Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions
I Abou Dalle, N Moukalled, J El Cheikh, M Mohty… - Leukemia, 2024 - nature.com
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …
distinctive cytogenetic entity associated with challenging outcomes, particularly in adult …
[HTML][HTML] Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML
Z Li, Y Xi, L Tu, X Zhang, Y Huang, H Nie… - Biomedicine & …, 2024 - Elsevier
Due to resistance and BCR-ABL T315I-mutated, CML remains a clinical challenge. It needs
new potential therapeutic targets to overcome CML resistance related to BCR-ABL. Our …
new potential therapeutic targets to overcome CML resistance related to BCR-ABL. Our …
Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute …
F Guan, L Yang, Y Chen, J Shi, X Song, X Lai, Y Lu… - Cancer, 2024 - Wiley Online Library
Background Although the prognosis of Philadelphia‐positive acute lymphoblastic leukemia
(Ph+ ALL) has improved with the introduction of tyrosine kinase inhibitors (TKIs) and stem …
(Ph+ ALL) has improved with the introduction of tyrosine kinase inhibitors (TKIs) and stem …
Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine …
J Zheng, Y Zhou, Y Zhao, Y Luo, J Yu, X Lai… - Annals of …, 2025 - Springer
The aim of this study was to develop and validate a nomogram predicting progression-free
survival (PFS) for adult patients with positive acute lymphoblastic leukemia (Ph+ ALL) who …
survival (PFS) for adult patients with positive acute lymphoblastic leukemia (Ph+ ALL) who …
[HTML][HTML] 费城染色体阳性急性淋巴细胞白血病治疗进展
杜小飞， 江明 - Advances in Clinical Medicine, 2023 - hanspub.org
费城染色体阳性急性淋巴细胞白血病(Ph+ ALL) 在成人中较常见, 发病率随年龄增长而增加,
恶性度较高, 传统的化疗效果不佳, 造血干细胞移植是治愈该疾病的手段, 在首次缓解期(CR1) …
恶性度较高, 传统的化疗效果不佳, 造血干细胞移植是治愈该疾病的手段, 在首次缓解期(CR1) …
[HTML][HTML] Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic …
Q Liu, TR Bian, ZY Li, HY Xing - Hematology, Transfusion and Cell Therapy, 2024 - Elsevier
Introduction: Flumatinib, a highly selective ABL kinase inhibitor, exhibits stronger inhibition
of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is …
of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is …
[PDF][PDF] Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
I In, CR ALL, II In - policy.asuris.com
BACKGROUND Broadly speaking, there are two types of hematopoietic cell transplants
(HCT, previously referred to in this policy as a hematopoietic stem cell transplant [HSCT]) …
(HCT, previously referred to in this policy as a hematopoietic stem cell transplant [HSCT]) …